Frank Roemer at the FDA workshop in June 2021 on how MRI and X-rays can help in screening process for patient eligibility in clinical trials.

In the recent FDA/Arthritis Foundation OA Drug Development Workshop: Assessment of Long-term Benefit on June 22nd, 2021 Dr. Roemer was invited as a speaker by the FDA to discuss Imaging Biomarkers in OA DMOAD trials and how these methods can help in the screening process to define potential eligible patients.